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ABSTRACT: Glucagon-like peptide-1 (GLP-1) has been shown to protect pancreatic
β-cells against cytokine-induced dysfunction and destruction. The mechanisms
through which GLP-1 exerts its eﬀects are complex and still poorly understood.
The aim of this study was to analyze the protein expression proﬁles of human islets of
Langerhans treated with cytokines (IL-1β and IFN-γ) in the presence or absence of
GLP-1 by 2D diﬀerence gel electrophoresis and subsequent protein interaction
network analysis to understand the molecular pathways involved in GLP-1-mediated
β-cell protection. Co-incubation of cytokine-treated human islets with GLP-1 resulted
in a marked protection of β-cells against cytokine-induced apoptosis and signiﬁcantly
attenuated cytokine-mediated inhibition of glucose-stimulated insulin secretion. The
cytoprotective eﬀects of GLP-1 coincided with substantial alterations in the protein
expression proﬁle of cytokine-treated human islets, illustrating a counteracting eﬀect
on proteins from diﬀerent functional classes such as actin cytoskeleton, chaperones,
metabolic proteins, and islet regenerating proteins. In summary, GLP-1 alters in an integrated manner protein networks in
cytokine-exposed human islets while protecting them against cytokine-mediated cell death and dysfunction. These data illustrate
the beneﬁcial eﬀects of GLP-1 on human islets under immune attack, leading to a better understanding of the underlying
mechanisms involved, a prerequisite for improving therapies for diabetic patients.
KEYWORDS: GLP-1, Type 1 diabetes, human islets, cytokines, 2D-DIGE, protein interaction networks
■ INTRODUCTION
Pro-inﬂammatory cytokines such as IL-1β, IFN-γ, and TNF-α
have been implicated as important mediators of β-cell dysfunc-
tion and destruction in type-1 diabetes and type-2 diabetes.1−3
The detrimental eﬀect of these cytokines on β-cell function and
survival is mediated via a complex network of cytokine-responsive
genes.4 Central in this regulation are intracellular signaling factors,
including nuclear factor κB (NF-κB) and signal transducer and
activator of transcription 1 (STAT1).5,6 In addition, pro-inﬂam-
matory cytokines have also been shown to induce β-cell apoptosis
by mediating endoplasmic reticulum (ER) Ca2+ depletion,
resulting in ER stress.7
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid incretin
hormone that is secreted from intestinal L cells, pancreatic α-
cells, and the caudal brain stem in a regulated manner.8 By
means of its regulatory actions on both pancreatic islets and
peripheral tissues, GLP-1 contributes to metabolic adaptation
to meal ingestion and overall glucose homeostasis.9 Moreover,
GLP-1 not only enhances the glucose sensing and insulin
secretory capacity of pancreatic islets10 but also inhibits β-cell
apoptosis and stimulates β-cell proliferation and islet neo-
genesis, thereby enhancing β-cell mass.11 Many of these eﬀects
are exerted by GLP-1-induced activation of adenylyl cyclase,
which leads to increased intracellular cAMP concentrations.
Downstream signaling is, among others, mediated by the
phosphatidylinositol 3-kinase (PI3K)−protein kinase B (PKB)/
Akt pathway, the PKA pathway, and cAMP response element-
binding (CREB) protein.12−14 Furthermore, GLP-1 also
controls glycaemia by inhibiting glucagon secretion and
suppressing hepatic glucose output as well as by decreasing
the rate of gastric emptying.15 Injectable GLP-1 receptor
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agonists and oral inhibitors of the natural enzyme degrading
GLP-1, dipeptidylpeptidase 4 (DPP-4), are currently widely
used as glucose-lowering agents in type-2 diabetes patients.16
The molecular mechanisms by which cytokines aﬀect β-cell
function and survival and by which GLP-1 may protect against
this inﬂammatory attack are still marginally understood. Here,
as a follow-up of previous studies by D’Hertog et al.17 and Tews
et al.,18 proteome analysis of human islets was performed using
2D diﬀerence gel electrophoresis (2D-DIGE) combined with
protein interaction network analysis. This increases our under-
standing of the mechanisms involved in these processes because
the current knowledge is largely based on RNA-based studies,19−25
while many forms of regulation take place at a post-transcriptional
level, such as post-translational modiﬁcations (PTMs) and
proteolytic degradation. Most importantly, these are also picked
up with this protein-based approach.26
We identiﬁed several cytokine- and/or GLP-1-responsive pro-
teins from diﬀerent functional classes indicating major changes
in actin cytoskeleton (re)organization, metabolism, chaperones,
and islet-regenerating proteins and revealed complex inter-
actions between these pathways. Understanding the cross-talks
and identifying molecular targets involved in cytokine-induced
β-cell dysfunction and destruction and the beneﬁcial eﬀects of
GLP-1 thereon thus increases our understanding of the physio-
logical and pharmacological eﬀects of GLP-1, a prerequisite
when attempting eﬀective therapeutic interventions for patients
with type-1 and type-2 diabetes.
■ METHODS
Human Islet Isolation
Islets were isolated by enzymatic digestion and gradient puri-
ﬁcation27,28 from pancreata of 14 multiorgan donors (age: 60 ±
17 years; male/female ratio: 6/8; BMI: 24.9 ± 4.2 kg/m2) and
cultured in M199 medium containing 5.5 mmol/L glucose,
supplemented with 10% (vol/vol) serum, 100 U/mL penicillin,
100 μg/mL streptomycin, 50 μg/mL gentamicin, and 750 ng/mL
amphotericin B (Sigma-Aldrich, St. Louis, MO).27,28 1000 islets
were incubated for 72 h either with or without 50 U/mL IL-1β
plus 1000 U/mL IFN-γ (Roche Diagnostics, Milan, Italy) and
with or without 10 nmol/L GLP-1 (Sigma-Aldrich, Milan,
Italy). The latter was replenished every 12 h.
Insulin Secretion Analysis
For insulin secretion studies, which were performed as
previously described,29,30 islets were ﬁrst kept at 37 °C for
45 min in Krebs−Ringer bicarbonate (KRB), 0.5% (vol/vol)
albumin, pH 7.4, containing 3.3 mmol/L glucose (wash-out
phase). Then, the medium was replaced with KRB containing
3.3 mmol/L glucose to assess basal insulin secretion (45 min),
followed by a further 45 min incubation with 16.7 mmol/L
glucose to assess insulin response to acute challenge. Insulin
was quantiﬁed by RIA (Pantec Forniture Biomediche, Turin,
Italy), and insulin secretion is expressed as a stimulation index,
corresponding to the ratio between stimulated (16.7 mmol/L
glucose) and basal (3.3 mmol/L glucose) insulin secretion.
Cell Death Analysis
Electron microscopy studies were performed at the end of the
previously described incubation conditions according to the
procedures previously described.29,30 Cells were considered
dead on the basis of the following criteria: loss of plasma
membrane integrity, fragmentation into discrete bodies,
engulfment of cell corpse, or its fragments by an adjacent
cell. The presence of marked chromatin condensation or blebs
was considered to be a sign of apoptosis. For morphometric
studies, 25 micrographs, obtained at ×10 000, were analyzed by
overlay with a graticule (11 × 11 cm) composed of 169 points.
For the study of insulin granules and mitochondria, volume
density (VD), expressed as mL/100 mL tissue (mL %), was
calculated according to the formula: VD = Pi/Pt, where Pi is
the number of points within the subcellular component and Pt
is the total number of points. 30−40 β-cells per islet, obtained
from three diﬀerent islet preparations, were analyzed per
condition.
2D-DIGE Analysis
Quadruplicate experiments were performed using islets from
four individual islet preparations. As for the experimental setup,
we analyzed four diﬀerent conditions, that is, control (n = 4),
GLP-1 (n = 4), IL-1β+IFNγ (n = 4), and the combination of
IL-1β+IFNγ with GLP-1 (n = 4). This resulted in a total of 16
samples, which were randomly run on 8 separate gels, assuring
that for each condition two “forward” gels (Cy3 labeled) and
two “reverse” gels (Cy5 labeled) were run. In addition, each gel
contained a pooled internal standard labeled with Cy2. For
each condition, 1000 human islets were treated as previously
described and collected and processed as follows. Islets were
washed twice in PBS and resuspended in 50 μL of 2D-DIGE
lysis buﬀer (7 mol/L urea; 2 M thiourea; 4% (w/v) CHAPS;
40 mM Trisbase; 1% (w/v) DTT; and a mixture of protease
inhibitors (Complete Protease Inhibitor, Roche Diagnostics,
Basel, Switzerland)). Samples were sonicated (ﬁve times 10 s
on ice, with an interval of 20 s on ice) and centrifuged for
15 min at 21 000g and 4 °C to remove cell debris. The
supernatant was desalted by dialysis (PlusOne Mini Dialysis kit,
GE Healthcare, Diegem, Belgium). 50 μg protein sample was
labeled with 200 pmol Cy3 or Cy5, while 50 μg of pooled
internal standard was labeled with 200 pmol Cy2. The internal
standard consisted of a pool of all control and treated samples
of all four replicate experiments. Labeling was performed accord-
ing to manufacturer’s instructions (GE Healthcare). Labeled
protein extracts were pooled, and sample loading buﬀer was
added (7 M Urea; 2 M Thiourea; 4% (w/v) CHAPS; 0.5% (v/v)
IPG buﬀer; and 1% (w/v) DTT). Protein samples were
separated in the ﬁrst dimension using the pH range 4−7 on 24
cm IPG strips (GE Healthcare). Therefore, IPG strips were
rehydrated overnight with rehydration buﬀer (7 M urea, 2 M
thiourea, 4% (w/v) CHAPS, 0.5% (v/v) IPG buﬀer, 0.05% (w/v)
OrangeG, and 1% (w/v) DTT). The ﬁrst dimension separation
was tracked using the Ettan IPGphor control software (version
1.01.03) (GE Healthcare) and was ended when the current
reached a stable phase (at ∼60 kV-h). Next, the strips were
equilibrated for two times 15 min in an equilibration buﬀer
(6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, and 50 mM Tris-
HCl, pH 8.8) containing 1% (w/v) DTT in the ﬁrst step and
4% (w/v) iodoacetamide and 0.02% bromphenol blue in the
second step. Equilibrated strips were then separated on a 12.5%
SDS-polyacrylamide gel in the second dimension on an Ettan
DaltSix system (GE Healthcare) at 8 mA/gel, 9 W, and 600 V
for 1 h and then at 16 mA/gel, 15 W, and 600 V until the
bromophenol blue dye front reached the bottom of the gel. The
gels were scanned using a Typhoon 9400 (GE Healthcare).
Initial scan parameters were press sample, depth plus 3 mm,
500 to 550 V photomultiplier tube setting, and 1000 μm pixel
size before repeating at 100 μm pixel size for a high-resolution
scan. Spot detection and matching was performed automatically
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using the BVA module of DeCyder version 7.0 software,
followed by careful manual rematching of wrongly matched
spots or unmatched spots. Spot detection parameters were set
as described by the manufacturer: spot detection algorithm 6.0,
estimated number of spots 10 000. The eight internal standards
from the eight gels were used to calculate average abundance.
For the analysis, we compared control (n = 4) versus IL-1β +
IFN-γ (n = 4), control (n = 4) versus GLP-1 (n = 4), and
IL-1β + IFN-γ (n = 4) versus IL-1β + IFN-γ + GLP-1 (n = 4).
Protein spot expression levels that showed a statistically
signiﬁcant (P < 0.05) increase or decrease in six out of eight
(Cy3 or Cy5 labeled) gels were accepted as being diﬀerentially
expressed.
Spot Digestion and Protein Identiﬁcation
For spot picking, four preparative gels were run (250 μg protein
lysate each). First and second dimension runs were performed
as described above, except that Cy dye-labeling was omitted.
Glass plates (27 × 21 cm) were pretreated with BindSilane, and
two reference markers were applied to enable automatic
picking. The gels (24 × 20 cm) were poststained using Krypton
(Pierce). Matching with the analytical gels was performed using
the BVA module of the DeCyder V7.0 software. A pick list was
generated and exported into the Spot Picker V1.20 software,
which controls the Ettan Spot Picker (GE Healthcare). Spots
were picked in Milli-Q water and rinsed three times with Milli-
Q water and three times with acetonitrile (LC-MS quality,
CHROMASOLV, Sigma-Aldrich). Next, the gels were hydrated
in 100 mM ammonium bicarbonate for 10 min, followed by a
dehydration step in 100% acetonitrile for 10 min with vigorous
vortexing. This step was repeated twice prior to dehydrating the
gel pieces in a SpeedVac. Gel pieces were then rehydrated in
digestion buﬀer (50 mM ammonium bicarbonate and 5 mM
calcium chloride) containing 5 ng/μL modiﬁed trypsin
(Promega, Madison, WI) and incubated overnight at 37 °C.
The resulting peptides were extracted out of the gel plugs in
four steps: once with 50 mM ammonium bicarbonate, twice
with 50% (v/v) acetonitrile and 5% (v/v) formic acid, and once
with 95% acetonitrile and 5% formic acid (30 min each).
Supernatants were dried in a SpeedVac. Samples were con-
centrated and desalted using Millipore C18 ZipTips. The peptides
were eluted in 10 μL of 70% acetonitrile and 0.1% formic acid and
dried in a SpeedVac. Samples were dissolved in 1 μL of α-cyano-4-
hydroxycinnamic acid matrix (saturated solution in 50%
acetonitrile and 0.1% triﬂuoroacetic acid in HPLC water), spotted
onto the MALDI target plate, and allowed to air-dry.
MS/MS analyses were performed on a 4800 MALDI TOF/
TOF (Applied Biosystems, Carlsbad, CA). The instrument was
calibrated with the Applied Biosystems Calibration Mixture 1.
The mass accuracy (external calibration) was <50 ppm in
reﬂection mode. Measurements were taken in the positive ion
mode between 900 and 3000 m/z. Sequences were automati-
cally acquired by scanning ﬁrst in MS mode and selecting the
15 most intense ions for MS/MS using an exclusion list of
peaks arising from tryptic autodigestion. Air was used as the
collision gas, while the collision energy was adapted automati-
cally. Data interpretation was carried out using the GPS
Explorer software (V3.6), and database searching was carried
out using the Mascot program (version 2.2.00). Because all
experiments were performed on human islets, searches were
conducted in the following database: UniProt_sprot (517 100
sequences; 182 146 551 residues, release date June 2010) with
the taxonomy set on Homo sapiens (20 367 sequences) using
the MS/MS data. Mass tolerance for precursor ions (peptide
tolerance) was set on 50 ppm, and on 0.4 Da for fragment ions
(MS/MS tolerance) methionine oxidation was selected as
variable modiﬁcation and carbamidomethylation of cysteine
was selected as ﬁxed modiﬁcation. Trypsin was selected as
enzyme and a maximum of one missed cleavage was allowed.
Using these parameters, the probability-based MOWSE scores
greater than the given cutoﬀ value for MS/MS fragmentation
data were taken as signiﬁcant (p < 0.05). Moreover, the individual
scores of the individual identiﬁed peptides were scrutinized for
their individual p value. Peptides with a p value >0.05 were
omitted, and the total score was recalculated as the sum of the
scores of the individual peptides with a p value <0.05 (Suppl.
Tables 1−3 in the Supporting Information). All additional mass
spectrometric information of the individual peptide sequences are
also provided in Suppl. Tables 1−3 in the Supporting Information.
We excluded the identiﬁcations that were based on single peptides,
and in the remaining cases where more than one protein could be
detected per spot we classiﬁed the multiple identiﬁcations with an
identical diﬀerential expression.
Western Blot Analysis
Human islets were lysed in 2D-DIGE lysis buﬀer for 15 min on
ice. Total cell lysate was sonicated and centrifuged (15 min at
21 000g and 4 °C), and afterward the supernatant was used for
Western blot analysis. The protein samples were separated on
4−12% BT gels (Invitrogen), blotted onto a PVDF membrane
(Hybond-ECL; GE Healthcare), and probed with goat anti-
REG1A (1:100), rabbit anti-REG1B (1:500), and goat anti-
TRPRS (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA)
and mouse anti-GAPDH (1:10,000) (Life Technologies, Ghent,
Belgium) as primary antibodies. The secondary antibodies
(1:5000), rabbit antigoat, goat antirabbit, and rabbit antimouse,
were from Dako. Western blots were incubated with the Western
lightning Plus-ECL detection system (PerkinElmer) and
exposed to Amersham Hyperﬁlm ECL-ﬁlms (GE Healthcare).
Network Analyses
Data were downloaded from MINT 48, BIND 49, IntAct 50,
KEGG, and Reactome. To increase the coverage of interactions,
interolog data 53 (the transfer of protein interactions between
orthologous protein pairs in diﬀerent organisms) were
included. Interactions from 17 eukaryotic organisms were
transferred and added to the network. Orthology was assigned
using the Inparanoid database 55 using stringent thresholds.
The statistical signiﬁcance of the networks was estimated using
a randomization scheme in which networks were generated
from random input sets of the same size as in the present
experiment. We performed 10 000 randomizations from which
we derived a probability distribution that was used to calculate
the signiﬁcance of the networks in this study.
Statistical Analysis
All data are presented as means ± SEM. For all experiments,
unless stated diﬀerently, comparisons were performed by two-
tailed unpaired t test. A p-value < 0.05 was considered
statistically signiﬁcant.
■ RESULTS
GLP-1 Counteracts the Inhibitory Eﬀect of Cytokines on
Glucose-Stimulated Insulin Secretion and Protects Human
Islet β-Cells against Cytokine-Induced Apoptosis
To assess the eﬀect of GLP-1 on cytokine-mediated β-cell
dysfunction and destruction, we incubated human islets
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for 72 h with or without IL-1β and IFN-γ, combined with GLP-
1 or its vehicle. Insulin release (μU/islet/min) from control
islets was 0.032 ± 0.004 at 3.3 mmol/L glucose and increased
to 0.107 ± 0.03 at 16.7 mmol/L glucose (Table 1). We
observed no signiﬁcant changes in glucose responsiveness upon
incubation with GLP-1 alone. Cytokine treatment was
associated with reduced glucose-stimulated insulin secretion
(GSIS), which was prevented upon coincubation with GLP-1
(Table 1). This was accompanied by a reduction in insulin
granule density in cytokine-treated islets, which was not
corrected by GLP-1 (Table 1 and Figure 1). Mitochondrial
VD increased signiﬁcantly after cytokine treatment from 3.1 ± 0.2
to 5.4 ± 0.9 mL % (p < 0.05), indicating cytokine-induced early
stage apoptosis (Table 2 and Figure 1). Co-incubation with
GLP-1 resulted in a mitochondrial VD of 3.9 ± 0.3 mL %,
corresponding to a partial inhibition of the observed cytokine
eﬀect. As for β-cell apoptosis, cytokine exposure induced a
signiﬁcant increase in the percentage of apoptotic β-cells from 1
± 0.6 to 18 ± 3.5% (p < 0.005), an eﬀect that was almost
completely prevented by coincubation with GLP-1 (Table 2).
Cytokine-Induced Alterations in Human Islet Protein
Expression: 2D-DIGE and Protein Identiﬁcations
Next, proteomic proﬁles of control and cytokine-treated islets
were determined using 2D-DIGE, revealing 58 diﬀerentially
expressed spots (p < 0.05) (Suppl. Figure 1 in the Supporting
Information), of which 45 could unambiguously be identiﬁed
by MALDI-TOF/TOF (identiﬁcation rate of 75%). On the
basis of literature searching, the identiﬁed proteins were grouped
in the same functional classes, as were used in previous
microarray22 and proteome17 analyses. Table 3 illustrates the com-
plete list of identiﬁed cytokine-modiﬁed proteins grouped accord-
ing to their function and includes information on the UniProt
accession number, fold regulation, and number of identiﬁed
peptides above identity threshold. Additional information is
provided in Suppl. Table 1 in the Supporting Information.
Cytokine Eﬀect on Metabolic Proteins
Cytokine treatment of human islets induced a signiﬁcant down-
regulation of ﬁve diﬀerent proteins involved in the mitochon-
drial respiratory chain (ATP synthase subunit beta and NADH
dehydrogenase (ubiquinone) iron−sulfur protein 3), the Krebs
cycle (succinyl-CoA ligase (GDP-forming) subunit beta),
alcohol metabolism (mitochondrial aldehyde dehydrogenase),
and ganglioside degradation (beta-hexosaminidase subunit
alpha). In addition to these down-regulated proteins, we also
observed a signiﬁcant cytokine-induced up-regulation of
cytoplasmic malate dehydrogenase, a protein involved in the
malate-aspartate shuttle.
Cytokine Eﬀect on Protein Synthesis, Folding, and
Modiﬁcation
Treatment of human islets with IL-1β/IFN-γ resulted in a
major, almost six-fold, down-regulation of the activator of
90 kDa heat shock protein ATPase homologue 1, which is a
chaperone that stimulates HSP90 ATPase activity and may be
involved in ER to Golgi traﬃcking. Furthermore, cytokine
treatment also resulted in a marked decrease in expression of
eukaryotic initiation factor 4A-I and II, both known to be
required for mRNA binding to ribosomes. Also note that three
down-regulated spots were found that contain two or more
chaperones, which makes it diﬃcult to conclude which of the
chaperones, if not all, are actually decreased upon cytokine
treatment.
Cytokine Eﬀect on Protein Degradation
Considering proteins involved in the regulation of protein
degradation, we observed a signiﬁcant, cytokine-mediated down-
regulation of two isoforms of the pancreatic exopeptidase carboxy-
peptidase A1. Moreover, cytokine treatment also resulted in a clear
up-regulation of the glycoprotein alpha-1-antichymotrypsin and
Table 1. Eﬀect of Cytokines and GLP-1 on Glucose-Stimulated Insulin Secretion and Insulin Granule Density in Human Islets
insulin at 3.3 mmol/L
glucose (μU/islet/min)a
insulin at 16.7 mmol/L
glucose (μU/islet/min)a
stimulation
index
stimulation index
(% from control) insulin granule (volume density, mL%)b
control 0.032 ± 0.004 0.107 ± 0.03 3.2 ± 0.6 100 7.1 ± 1.0
GLP-1 0.031 ± 0.002 0.097 ± 0.02 3.0 ± 0.4 101 ± 11 7.7 ± 1.0
cytokines 0.040 ± 0.005 0.079 ± 0.01 2.0 ± 0.3 67 ± 6c 3.9 ± 0.6d
cytokines + GLP-1 0.035 ± 0.003 0.107 ± 0.02 3.0 ± 0.5 99 ± 10 3.5 ± 0.6d
aData from six diﬀerent islet preparations. bData from 30 to 40 β-cells for each diﬀerent experimental condition. The stimulation index was
calculated by dividing the measured insulin values from the 16.7 mmol/L glucose samples by the insulin values from the 3.3 mmol/L glucose
samples. cp < 0.05 vs all other groups after Bonferroni correction. dp < 0.05 vs control and GLP-1 after Bonferroni correction.
Figure 1. Eﬀect of cytokines and/or GLP-1 on human islet function
and destruction. Representative micrographs of (A) control, (B) GLP-
1-treated, (C) IL-1β- and IFN-γ-treated, and (D) IL-1β-, IFN-γ-, and
GLP-1-treated pancreatic islets. IG, insulin granules; GG, glucagon
granules; M, mitochondrion; N, nucleus (magniﬁcations: ×10 000).
Table 2. Eﬀect of Cytokines and GLP-1 on β-Cell Apoptosis
and Morphology of Mitochondria in Human Isletsa
apoptosis
(%) mitochondria (volume density, mL%)
control 1 ± 0.6 3.1 ± 0.2
GLP-1 1 ± 0.6 3.5 ± 0.3
cytokines 18 ± 3.5b 5.4 ± 0.9b
cytokines + GLP-1 4 ± 1.2 3.9 ± 0.3
aData from three diﬀerent islet preparations. bp < 0.05 vs all other
groups after Bonferroni correction.
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Table 3. Identiﬁcation of Proteins with an Altered Expression Proﬁle upon IL-1β and IFN-γ Treatment of Human Islets
Compared with Controls
spot no. full protein name
abbrev protein
name
UniProt
accesion no. pIa MW (kDa)a t test
fold
regulation
no. of peptides
sequenced
1. metabolism
up-regulated
1597 malate dehydrogenase, cytoplasmic MDHC P40925 6.89 36.3 0.003 4.51 2
down-regulated
930 ATP synthase subunit beta,
mitochondrial
ATPB P06576 5.26 56.6 0.021 −1.52 3
934 beta-hexosaminidase subunit alpha HEXA P06865 5.04 60.7 0.033 −1.98 2
959 aldehyde dehydrogenase, mitochondri-
al
ALDH2 P05091 6.63 56.4 0.036 −1.65 3
1339 succinyl-CoA ligase [GDP-forming]
subunit beta, mitochondrial
SUCB2 Q96I99 6.15 46.5 0.021 −1.72 2
2072 NADH dehydrogenase [ubiqui-
none] iron−
sulfur protein 3, mitochondrial
NDUS3 O75489 6.98 30.2 0.017 −1.91 6
2. protein synthesis, fold-
ing, modiﬁcation and
secretion
down-regulated
519 peptidyl-prolyl cis−
trans isomerase FKBP9
FKBP9 O95302 4.91 63.1 0.020 −2.23 2
protein disulﬁde-isomerase A2 PDIA2 Q13087 4.89 58.2 0.020 −2.23 6
heat shock 70 kDa protein 1A/1B HSP71 P08107 5.48 69.9 0.020 −2.23 2
526 78 kDa glucose-regulated protein GRP78 P11021 5.07 72.3 0.035 −1.53 2
heat shock 70 kDa protein 1A/1B HSP71 P08107 5.48 69.9 0.035 −1.53 4
1122 eukaryotic initiation factor 4A-I IF4A1 P60842 5.32 46.0 0.024 −1.68 3
thioredoxin domain-containing
protein 5
TXND5 Q8NBS9 5.63 47.6 0.024 −1.68 2
1131 eukaryotic initiation factor 4A-II IF4A2 Q14240 5.33 46.4 0.026 −2.04 3
eukaryotic initiation factor 4A-I IF4A1 P60842 5.32 46.0 0.026 −2.04 3
1275 activator of 90kDa heat shock protein
ATPase homologue I
AHSA1 O95433 5.41 38.1 0.009 −5.92 4
3. protein degradation
up-regulated
903 alpha-1-antichymotrypsin SERPINA3 P01011 5.33 47.7 0.036 1.31 2
950 cytosol aminopeptidase AMPL P28838 8.03 56.2 0.0022 3.18 4
970 cytosol aminopeptidase AMPL P28838 8.03 56.2 0.0022 5.47 13
down-regulated
1282 carboxypeptidase A1 CBPA1 P15085 5.45 47.1 0.023 −3.35 2
1286 carboxypeptidase A1 CBPA1 P15085 5.45 47.1 0.039 −1.54 3
4. cytoskeleton, vesicle
motility/intracellular
transport/vesicle release
up-regulated
416 moesin MOES P26038 6.09 67.7 0.04 2.47 2
caldesmon CALD1 Q05682 5.62 93.2 0.04 2.47 2
492 moesin MOES P26038 6.09 67.7 0.033 1.48 2
878 tubulin beta chain TBB5 P07437 4.78 49.7 0.0031 3.08 11
down-regulated
526 lamin-B1 LMNB1 P20700 5.11 66.0 0.035 −1.53 2
834 vimentin VIME P08670 5.05 53.5 0.028 −1.55 7
1063 actin-related protein 3 ARP3 P61158 5.61 47.2 0.022 −3 4
1069 actin-related protein 3 ARP3 P61158 5.61 47.2 0.039 −1.91 3
1217 synaptic vesicle membrane
protein VAT-1 homologue
VAT1 Q99536 5.88 41.8 0.048 −2.17 7
1278 actin, cytoplasmic 1 ACTB P60709 5.29 41.7 0.0068 −3.41 7
1282 actin, cytoplasmic 1 ACTB P60709 5.29 41.7 0.023 −3.35 3
1286 actin, cytoplasmic 1 ACTB P60709 5.29 41.7 0.039 −1.54 7
1339 tropomodulin-3 TMOD3 Q9NYL9 5.08 39.6 0.021 −1.72 2
1804 F-actin-capping protein subunit beta CAPZB P47756 5.36 31.2 0.0004 −1.66 8
2028 heat shock protein beta-1 HSPB1 P04792 5.98 22.8 0.019 −2.2 3
2069 heat shock protein beta-1 HSPB1 P04792 5.98 22.8 0.042 −2.06 3
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two cytosol aminopeptidase isoforms, which are known to be involved
in the processing and regular turnover of intracellular proteins.
Cytokine Eﬀect on Cytoskeleton and Vesicle Motility
Among all of the protein alterations observed, cytokine
exposure of human islets had the most dramatic eﬀect on the
group of proteins involved in cytoskeleton organization and
vesicle motility. Here several proteins involved in actin
(de)polymerization (β-actin, actin-related protein 3, tropomo-
dulin-3, F-actin-capping protein subunit beta, and heat shock
protein beta-1) were signiﬁcantly down-regulated. Furthermore,
we observed an up-regulation of tubulin β-chain TBB5 − a
major component of microtubules, caldesmon − a calmodulin-
and actin-binding protein known to regulate ATPase activity of
spot no. full protein name
abbrev protein
name
UniProt
accesion no. pIa MW (kDa)a t test
fold
regulation
no. of peptides
sequenced
2072 heat shock protein beta-1 HSPB1 P04792 5.98 22.8 0.017 −1.91 6
2076 heat shock protein beta-1 HSPB1 P04792 5.98 22.8 0.011 −1.78 4
5. RNA synthesis/turnover
down-regulated
959 heterogeneous nuclear ribonucleopro-
tein H
HNRH1 P31943 5.89 49.2 0.036 −1.65 7
1069 spliceosome RNA helicase DDX39B DX39B Q13838 5.44 49.0 0.039 −1.91 5
6. tRNA synthesis/turn-
over
up-regulated
919 tryptophanyl-tRNA synthetase,
cytoplasmic
SYWC P23381 5.83 53.0 0.031 5.92 4
955 aspartyl-tRNA synthetase, cytoplasmic SYDC P14868 6.11 57.1 0.021 2.7 8
down-regulated
921 tryptophanyl-tRNA synthetase,
cytoplasmic
SYWC P23381 5.83 53.0 0.041 −2.58 2
7. cell cycle and rela-
ted genes
down-regulated
1952 prohibitin PHB P35232 5.57 29.8 0.045 −1.87 7
8. defense and repair
up-regulated
2377 lithostathine-1-alpha // Islet of
Langerhans regenerating protein
REG1A P05451 5.65 18.7 0.0009 2.51 7
down-regulated
2407 lithostathine-1-alpha // Islet of
Langerhans regenerating protein
REG1A P05451 5.65 18.7 0.0018 −3.98 2
2485 lithostathine-1-alpha // Islet of
Langerhans regenerating protein
REG1A P05451 5.65 18.7 0.01 −2.93 5
2513 lithostathine-1-beta // regenerat-
ing islet-derived protein 1-beta
REG1B P48304 5.67 18.7 0.014 −5.02 7
9. apoptosis
down-regulated
1923 cathepsin D CATD P07339 6.10 44.6 0.03 −2.94 14
1938 cathepsin D CATD P07339 6.10 44.6 0.015 −3.26 10
1942 cathepsin D CATD P07339 6.10 44.6 0.0036 −3.63 12
1968 cathepsin D CATD P07339 6.10 44.6 0.022 −2.2 10
2021 cathepsin D CATD P07339 6.10 44.6 0.041 −1.82 2
2113 cathepsin B CATB P07858 5.88 37.8 0.0057 −1.79 7
10. miscellaneous
up-regulated
890 neurosecretory protein VGF VGF O15240 4.76 67.3 0.0033 2.57 7
down-regulated
1146 eukaryotic initiation
factor4A-III//ATP-dependent RNA
helicase DDX48
IF4A3 P38919 6.30 46.9 0.05 −1.4 7
1275 plasminogen activator inhibitor 2 SERPINB2 P05120 5.46 46.6 0.0085 −5.92 3
1282 selenide, water dikinase 1 SPS1 P49903 5.64 42.8 0.023 −3.35 2
1383 serpin B6 SERPINB6 P35237 5.18 42.6 0.03 −2.2 3
1401 serpin B6 SERPINB6 P35237 5.18 42.6 0.026 −2.05 6
aTheoretical values for pI and MW were retrieved from the ExPASy Bioinformatics Resource Portal (http://web.expasy.org/compute_pi/).
Table 3. continued
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myosin and two isoforms of moesin that functions as a cross-
linker between the plasma membrane and actin-based
cytoskeleton. These data, together with the observed down-
regulation of the intermediate ﬁlament protein vimentin,
indicate that cytokine treatment of human islets interferes
with the three major components of the cytoskeleton, namely,
the actin-based microﬁlaments, the tubulin-based microtubules,
and the intermediate ﬁlaments. Finally, also the synaptic vesicle
membrane protein VAT-1 homologue, known to be involved in
vesicular transport and lamin B1, were found down-regulated
upon cytokine treatment. The latter may be associated with the
observed increased apoptosis rate because disassembly of lamin
B1 represents one of the various features of apoptotic cells.
Cytokine Eﬀect on Defense and Repair
In the functional group of proteins involved in cellular defense
and repair, both REG1A and REG1B, known to be involved in
β-cell proliferation and neogenesis,31 were altered upon
cytokine treatment. As for REG1A, one isoform was up-
regulated, whereas two other isoforms were signiﬁcantly down-
regulated by cytokine exposure of the islets. On the basis of the
position of the three isoforms on the 2D gel (Figure 2A and
Suppl Figure 1 in the Supporting Information), these
alterations are suggestive for post-translational modiﬁcation of
REG1A. As for REG1B, we observed decreased expression
levels of the protein upon cytokine treatment (Figure 2B).
Expression levels of both proteins were also analyzed on 1DE
(Figure 2C), indicating no cytokine eﬀect on total REG1A
expression levels and a clear down-regulation of REG1B
expression levels by cytokine treatment, further conﬁrming the
2D-DIGE data.
Cytokine Eﬀect on tRNA Synthesis and Turnover
In this functional group, aspartyl-tRNA synthetase was up-
regulated upon cytokine treatment of human islets. As for
tryptophanyl-tRNA synthetase (TRPRS), one isoform (spot
number 919) was found up-regulated, whereas another isoform
(spot number 921) was found down-regulated. Further analysis
of the position of both isoforms on the 2D-DIGE gels sug-
gested the possible post-translational modiﬁcation of cytoplasmic
TRPRS upon cytokine treatment (Figure 3A). The expression
level of the latter was also analyzed on 1DE (Figure 3B),
indicating cytokine-induced expression levels of total TRPRS,
most likely due to a proportional higher increase in the ﬁrst
isoform as compared with the induced decrease in the second
isoform.
Protein Alterations Induced by GLP-1 in Control and
Cytokine-Treated Human Islets
First of all, we investigated the eﬀect of GLP-1 on the basal
protein proﬁle of human islets. Overall, only a minor eﬀect on
the protein proﬁle was observed with a total of 10 identiﬁed
protein expression alterations (Table 4 and Suppl. Figure 2 and
Suppl. Table 2 in the Supporting Information).
Second, to identify players responsible for the beneﬁcial
eﬀect of GLP-1 on cytokine-treated human islets, the pro-
teomic proﬁle of human islets exposed for 72 h to IL-1β/IFN-γ,
combined with GLP-1, was determined. Compared with cytokine-
treated islets, 16 spots were observed as diﬀerentially expressed
by cotreatment with GLP-1 (p < 0.05) (Suppl. Figure 3 in the
Figure 2. Regulation of REG1A and REG1B isoforms after cytokine
treatment. (A) REG1A and (B) REG1B isoforms after IL-1β and IFN-
γ treatment. Each isoform is illustrated by two representative 3D
images, one of control (Ctrl) and one of cytokine-treated islets (Cyt)
and the graph view of the DeCyder analysis (n = 4) for each particular
spot with the standardized log abundance in the y axis. (C) Total
REG1A and REG1B protein levels of control or cytokine-treated islets.
A representative image of a Western blot is shown (n = 3).
Figure 3. Regulation of TRPRS after cytokine treatment. (A) Each
isoform is illustrated by two representative 3D images, one of control
(Ctrl) and one of cytokine-treated islets (Cyt), and the graph view of
the DeCyder analysis (n = 4) for each particular spot with the
standardized log abundance in the y axis. (B) Total TRPRS protein
levels of control or cytokine-treated islets. A representative image of a
Western blot is shown (n = 3).
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Supporting Information). Of these, 14 spots were unambigu-
ously identiﬁed by MALDI-TOF/TOF, which corresponds to
an overall identiﬁcation rate of 87.5%. Table 5 and Suppl.
Table 3 in the Supporting Information show the complete list
of identiﬁed proteins grouped in diﬀerent functional classes.
Most interestingly, the majority of GLP-1-induced changes
were observed in the functional class of the cytoskeleton and
vesicle motility, which is in line with the protective eﬀect of
GLP-1 observed on apoptosis rate and GSIS. In this class, one
of the two isoforms of ARP3, which is signiﬁcantly decreased in
cytokine-treated human islets (Table 3), is completely normalized
upon coincubation with GLP-1 (Figure 4A). Furthermore, also
two isoforms of the F-actin-capping protein subunit α1 were
up-regulated upon GLP-1 treatment as compared with control
cytokine-treated human islets. As for protein synthesis and
processing, GLP-1 attenuated mitochondrial Stress-70 protein
expression levels, whereas it augmented EIF3I expression in
human islets treated with cytokines. In the functional class of
defense and repair, two proteins, REG1A and UBE2N, are
negatively regulated by GLP-1 as compared with the control
cytokine-treated condition. As previously described, this
REG1A isoform is found upregulated due to cytokine treatment
as compared with control human islets (Figure 4B). Finally, we
also observed a GLP-1-induced up-regulation of the metabolic
protein pyruvate dehydrogenase beta that acts as an essential
link between glycolysis and Krebs cycle.
Network Analysis
To investigate whether the identiﬁed, diﬀerentially expressed
proteins work together in speciﬁc networks, we analyzed the
potential interactions between these proteins making use of a
sophisticated network program recently developed32 (Figure 5).
This allowed us to examine whether the diﬀerentially expressed
proteins from one or more functional pathways interact with
each other and to place them in a framework of cellular
systems. Note that to construct these networks we also
considered ﬁrst-order interaction partners (gray circles) of the
identiﬁed proteins because these linker proteins enable us to
get a more complete view on the proteins and pathways
aﬀected by each treatment.
The network generated for cytokine-treated human islets
includes 30 out of 58 distinct proteins identiﬁed (p < 1.0 × 10−4).
As shown in Figure 5B, this complex network contains proteins
from diﬀerent functional classes, suggesting extensive cross-talk
between the proteins and pathways in which they are involved.
This indicates that cytokine treatment of human islets results in
a complex interaction between proteins from diﬀerent func-
tional classes, ﬁnally resulting in the observed cytokine-induced
eﬀects on β-cell function and destruction. Central in this
Table 4. Identiﬁcation of Proteins with an Altered Expression Proﬁle upon GLP-1 Treatment of Human Islets Compared to
Controls
spot no. full protein name
abbrev protein
name
UniProt
accesion no. pIa MW (kDa)a t test
fold
regulation
no. of peptides
sequenced
1. metabolism
up-regulated
325 pyridoxal-dependent decarboxylase
domain-containing protein 1
PDXD1 Q6P996 5.25 86.7 0.045 1.49 3
down-regulated
961 ATP synthase subunit beta,
mitochondrial
ATPB P06576 5.26 56.6 0.035 −1.54 2
979 ATP synthase subunit beta,
mitochondrial
ATPB P06576 5.26 56.6 0.03 −1.53 10
989 ATP synthase subunit beta,
mitochondrial
ATPB P06576 5.26 56.6 0.011 −1.59 12
1165 guanine deaminase GUAD Q9Y2T3 5.44 51.0 0.043 −1.36 2
2. protein synthesis,
folding, modiﬁcation
and secretion
down-regulated
1434 glutaminyl-peptide cyclotransferase QPCT Q16769 6.12 40.9 0.027 −1.44 2
3. protein degradation
up-regulated
328 26S proteasome non-ATPase
regulatory subunit 2
PSMD2 Q13200 5.08 100.2 0.014 2.41 9
down-regulated
288 transitional endoplasmic reticulum
ATPase
TERA P55072 5.14 89.2 0.041 −1.98 6
1096 26S protease regulatory subunit 6A PRS6A P17980 5.13 49.2 0.043 −1.76 2
4. cytoskeleton, vesicle
motility/intracellular
transport/vesicle
release
down-regulated
1804 F-actin-capping protein subunit beta CAPZB P47756 5.36 31.2 0.042 −1.33 8
1928 secretagogin SEGN O76038 5.25 32.0 0.041 −1.38 3
5. miscellaneous
up-regulated
325 shootin-1 SHOT1 A0MZ66 5.27 71.6 0.045 1.49 2
aTheoretical values for pI and MW were retrieved from the ExPASy Bioinformatics Resource Portal (http://web.expasy.org/compute_pi/).
Journal of Proteome Research Article
dx.doi.org/10.1021/pr400527q | J. Proteome Res. 2013, 12, 4193−42064200
network are the proteins involved in the organization of the
cytoskeleton and vesicle motility (green circles). As shown in
Figure 5C, the network generated for cytokine- and GLP-1-
treated human islets (as compared with cytokine-treated
islets) includes 8 out of 13 diﬀerentially expressed proteins
(p < 1.0 × 10−6) with again a central role for 4 proteins
involved in cytoskeleton organization and vesicle motility
(green circles). Thus, these networks suggest an important
role for structural proteins such as ACTB, ARP3, and
CAZA1 in both cytokine-induced β-cell dysfunction and
destruction and the protective eﬀect of GLP-1 on cytokine-
treated β-cells.
■ DISCUSSION
In this study, we investigated the protective eﬀects of GLP-1 on
human islets of Langerhans in a setting relevant for both type-1
and type-2 diabetes, namely, in vitro exposure of whole human
islets to the pro-inﬂammatory cytokines IL-1β and IFN-γ. To
investigate the underlying molecular pathways associated with
the observed eﬀects of GLP-1 on β-cell dysfunction and
destruction, we performed a full proteome and protein
interaction network analysis. Because 72 h of cytokine
treatment resulted in only 18 ± 3.5% apoptotic β-cells, we
decided to maintain these culture conditions for proteomic
analysis, which thereby allowed us to identify networks of
Table 5. Identiﬁcation of Proteins with an Altered Expression Proﬁle upon IL-1β, IFN-γ, and GLP-1 Treatment of Human Islets
Compared to IL-1β and IFN-γ Treatment
spot no. full protein name
abbrev protein
name
UniProt
accesion no. pIa MW (kDa)a t test
fold
regulation
no. of peptides
sequenced
1. metabolism
up-regulated
958 aldehyde dehydrogenase, mitochondri-
al
ALDH2 P05091 6.63 56.4 0.04 1.38 2
1563 pyruvate dehydrogenase E1 compo-
nent subunit beta, mitochondrial
ODBP P11177 6.20 39.2 0.01 1.99 4
2.proteinsynthesis,fold-
ing, modiﬁca-
tion and secretion
up-regulated
1501 eukaryotic translation initiation fac-
tor 3 subunit I
EIF3I Q13347 5.38 36.5 0.04 1.75 3
down-regulated
501 stress-70 protein, mitochondrial GRP75 P38646 5.87 73.7 0.02 −1.5 4
3. signal transduction
down-regulated
1704 annexin A3 ANXA3 P12429 5.63 36.2 0.03 −2.08 4
4. cytoskeleton, vesi-
cle motility/intracel-
lular transport/vesi-
cle release
up-regulated
1063 actin-related protein 3 ARP3 P61158 5.61 47.2 0.05 1.73 4
1373 actin, cytoplasmic 1 ACTB P60709 5.29 41.7 0.02 2.69 3
1557 F-actin-capping protein subunit al-
pha-1
CAZA1 P52907 5.45 32.8 0.05 1.61 6
1563 F-actin-capping protein subunit al-
pha-1
CAZA1 P52907 5.45 32.8 0.01 1.99 5
down-regulated
1704 annexin A4 ANXA4 P09525 5.84 35.8 0.03 −2.08 5
5. RNA synthesis/turn-
over
up-regulated
958 heterogeneous nuclear ribonucleopro-
tein H
HNRH1 P31943 5.89 49.2 0.04 1.38 2
6. defense and repair
down-regulated
2377 lithostathine-1-alpha // Islet of Langer-
hans regenerating protein
REG1A P05451 5.65 18.7 0.01 −1.85 7
2463 ubiquitin-conjugating enzyme E2 N UBE2N P61088 6.13 17.1 0.02 −1.51 2
7. miscellaneous
down-regulated
625 guanylate-binding protein 5 GBP5 Q96PP8 5.38 66.3 0.05 −1.35 5
aTheoretical values for pI and MW were retrieved from the ExPASy Bioinformatics Resource Portal (http://web.expasy.org/compute_pi/).
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proteins directly associated with the observed cytotoxic eﬀect of
cytokines and most importantly the cytoprotective action of
GLP-1. Indeed, human islets are somewhat less susceptible to
treatment with the combination of IL-1β and IFN-γ, as com-
pared with INS-1E cells, where a similar percentage of apoptotic
cells is already reached after 24 h of treatment.17 The use of
whole human islets enabled us to conﬁrm diﬀerent important
pathways that are involved in cytokine-mediated β-cell
destruction, extending our previous ﬁndings in rodent-derived
INS-1E cells toward a more physiological model.17 GLP-1 by
itself aﬀected the proteome proﬁle of human islets only in a
minor way, with only 10 proteins altered versus unexposed
islets. However, when human islets were treated with the
cytokine mixture IL-1β and IFN-γ, inducing increased apoptosis
and decreased GSIS, a clear cytoprotective eﬀect of GLP-1 was
observed upon coincubation, correlating with published in vitro
studies in human islets14 and in vivo studies in murine models.33−35
Of note, despite the restoring eﬀect of GLP-1 on cytokine-
mediated inhibition of GSIS, GLP-1 did not alter the cytokine-
mediated decrease in insulin granule density. A possible
explanation for this apparent contradiction might be that
GLP-1 positively aﬀects the exocytotic machinery (reviewed in
ref 36) but has no eﬀect on cytokine-mediated decrease in
insulin production and thereby insulin granule density.
To analyze the proteome of cytokine- and GLP-1-treated
human islets, we used high-resolution 2D-DIGE. Although
more labor-intensive and somewhat less sensitive compared
with gel-free proteomic techniques such as iTRAQ, this
technique has the advantage to provide information on the
mass and isoelectric point of the detected proteins, enabling us
to detect post-translational modiﬁcations of speciﬁc proteins.
The latter, in particular, may play an important role in the
Figure 5. Network analysis of the identiﬁed diﬀerential expressed proteins after cytokine or GLP-1 treatment. (A) Treatment with 10 nM GLP-1
(p < 0.001 compared with control islets). (B) Treatment with IL-1β and IFN-γ (p < 1.0 ×10−4 compared with control islets) and (C) treatment with
IL-1β, IFN-γ, and GLP-1 (p < 1.0 ×10−6 compared with IL-1β- and IFN-γ-treated islets). Colored circles represent proteins that were identiﬁed in
this study and gray circles represent interconnecting proteins revealed by the network software program. The identiﬁed proteins were colored
according to their function as indicated in the Figure.
Figure 4. Regulation of ARP3 and REG1A after cytokine treatment
with or without GLP-1. (A) ARP3 (spot 1063) and (B) REG1A (spot
2377). The respective intensities of the diﬀerent CyDye-labeled
isoforms of control (Ctrl), cytokine-treated (Cyt), and cytokine +
GLP-1-treated (Cyt + GLP-1) human islets were quantiﬁed and
expressed as standardized log abundance in the graph view (n = 4).
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loss of immune tolerance during the development of type-1
diabetes.37
Analysis of the mass spectrometry data revealed that the
majority of the identiﬁed proteins are, consistent with previous
studies performed on rat islets,38,39 involved in protein synthesis
and degradation, cytoskeleton (re)organization, and metabo-
lism. One of the characteristic features of β-cells is a highly
developed ER to fold, process, and export newly synthesized
insulin.40 It is thereby also believed that β-cells represent one of
the most susceptible cell types for ER stress. Moreover, a recent
publication from Fonseca and colleagues41 illustrates an impor-
tant role for the ER protein Wolfram syndrome 1 (WFS1) as a
regulator of both the ER stress signaling pathway and glucose-
and GLP-1-induced insulin secretion. Central in the cellular
protection mechanism against ER stress, called the unfolded
protein response (UPR), are the ER chaperones, which are
involved in protein folding and prevention of aggregation of
unfolded or misfolded proteins. In line with our previously
published data on INS-1E cells17 and the previous report on
IL-1β-treated rat islets,39 we observed several ER chaperones
that were down-regulated upon cytokine treatment of human
islets, which may partially explain the cytotoxic eﬀect of
cytokines on β-cells. More speciﬁcally, EIF4A isoforms 2 and 1
were identiﬁed as being down-regulated upon cytokine
exposure of human islets. This cytokine-mediated decrease in
EIF4A expression levels can inhibit cap-dependent insulin
biosynthesis in β-cells.42 GLP-1 had pronounced counteractive
eﬀects on the cytokine-induced alterations of these ER stress-
related proteins. As such, the observed GLP-1-mediated up-
regulation of EIF3I, a translation initiation factor that is shown to
play a prominent role in ﬁbroblast proliferation,43 might attenuate
the cytokine-mediated decrease in EIF4A expression. In addition,
on the basis of the reported functional role of GRP75 in cytokine-
mediated β-cell destruction, indicating a positive correlation
between GRP75 expression levels in rat islets and cytokine
susceptibility,44 also the GLP-1-mediated down-regulation of
GRP75 is consistent with the protective eﬀect of GLP-1 against
cytokine-induced β-cell death. However, in contrast with
Johannesen and colleagues,44 we were not able to identify a
signiﬁcant increase in GRP75 expression following cytokine
treatment, which might be due to diﬀerences in experimental
setup such as the usage of human islets, as opposed to rodent
islets, treatment with diﬀerent cytokines, and diﬀerent incubation
times.
Another functional class strongly aﬀected by cytokine as well
as GLP-1 exposure of human islets was the class of proteins
involved in cytoskeleton organization and vesicle motility. It is
well-established that the actin cytoskeleton and its remodeling
are crucial to GSIS. Moreover, this remodeling process has
been shown to be indispensable for insulin granules to get in
close proximity with their docking sites as well as for activating
speciﬁc compounds of the exocytotic machinery such as the
t-SNARE complex, thereby facilitating docking and fusion of
the insulin secretory granules with the plasma membrane and
secretion of their content.45,46 In addition, we already observed
and described the eﬀect of a 24 h cytokine treatment on the
reorganization of ﬁlamentous actin (F-actin) in rodent INS-1E
cells.17 The dynamic assembly and disassembly of ﬁlaments and
the formation of larger scale ﬁlament structures, F-actin out of
monomeric G-actin, are crucial aspects of the function of actin
and are therefore under scrupulous control by over 100 actin-
binding proteins.47 In this study, we identiﬁed multiple
cytokine- and GLP-1-responsive proteins such as actin-related
protein 3 (ARP3), F-actin-capping protein subunit beta (CAPZB),
and heat shock protein beta-1 (HSPB1), which are involved in
F-actin polymerization48,49 as well as proteins such as tropo-
modulin-3 (TMOD3), which is involved in actin depolymeriza-
tion.50 Cytokine-mediated down-regulation of these proteins in
human β-cells most likely disrupts the dynamic equilibrium
between monomeric G-actin and ﬁlamentous F-actin and in
this way inhibits GSIS. Interestingly, these changes were found
to be counteracted by GLP-1 through an up-regulation of
ARP3 and the F-actin-capping protein subunit α1. This GLP-1
eﬀect might hence, at least partially, restore the disrupted
equilibrium, thereby normalizing the cytokine-mediated in-
hibition of GSIS.
Similar to Tews and colleagues,18 we also observed a cytokine-
mediated down-regulation of proteins involved in the electron-
transport chain, which can be linked to oxidative stress and
eventually to apoptosis. In contrast with this previous study, we
did not observe a normalizing eﬀect of GLP-1 on the expre-
ssion levels of these proteins. This apparent discrepancy might
be explained by the diﬀerent setups used in both approaches
(e.g., INS-1E cell line vs human islets and analysis of mito-
chondrial fraction vs full lysates). We observed a GLP-1-induced
normalization of the cytokine-mediated decrease in mitochon-
drial aldehyde dehydrogenase, which possibly functions as a
protection against the cytokine-induced production of cytotoxic
aldehydes.51 Furthermore, cytokine treatment of human islets
also resulted in the down-regulation of mitochondrial Succinyl-
CoA ligase [GDP-forming] subunit beta, which is known to
have a negative impact on the Krebs cycle and GSIS.52 This
might be counteracted by the GLP-1-induced expression and
activation of the mitochondrial pyruvate dehydrogenase E1
component subunit beta, which functions, in its complex, as the
primary link between glycolysis and the Krebs cycle and
thereby positively aﬀects GSIS.53 These data correspond with
the ﬁndings of Sparre and colleagues,39 who showed a reduced
energy production in rat islets upon IL-1β exposure.
Furthermore, we also observed a clear eﬀect on REG1A and
REG1B, which are acinar cell-derived proliferation factors
shown to be involved in β-cell proliferation.54 Several members
of the Reg gene family have already been identiﬁed as being
induced by GLP-1,55 although this is the ﬁrst report in human
islets. However, overexpression of REG1 has also been
associated with accelerated diabetes in NOD mice56 and has
been shown to inhibit β-cell growth and possibly induces
apoptosis.54 This dual action is probably reﬂected in the
observed diﬀerential eﬀect of cytokines on the expression
proﬁles of REG1A and REG1B. Indeed, we observed an
opposite regulation of diﬀerent PTM-isoforms of the Reg
family members. Interestingly, GLP-1-mediated down-regula-
tion of the cytokine-induced REG1A isoform might be able to
normalize the detrimental eﬀect of this increase in REG1A
expression. Although the exact nature and role of the observed
PTMs need further investigation, this ﬁnding points to an
important role of PTMs in the protective eﬀect of GLP-1.
In summary, we conﬁrm the protective eﬀect of GLP-1
against cytokine-induced β-cell dysfunction and destruction in
human islets of Langerhans. In addition, this study provides the
ﬁrst protein expression proﬁle of GLP-1-exposed human β-cells
in their physiological environment, namely, intact human islets.
These data support the diversity and complexity of the
underlying, both protective and deleterious, mechanisms
implicated in cytokine-mediated β-cell dysfunction and
destruction underlining the importance of proteins of diﬀerent
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functional classes, such as chaperones, cytoskeleton reorganiza-
tion, metabolism, and islet regenerating proteins. In addition,
the analysis of quantitative changes in protein expression levels
and elucidation of protein interaction networks revealed that
the cytoprotective eﬀects of GLP-1 are mainly executed
through counteracting the eﬀects of cytokines on these same
pathways/proteins. These observations may be important in
the context of type-1 diabetes, where immune cells and immune
cytokines have been described to contribute to β-cell dysfunc-
tion. Clinical trials evaluating a putative beneﬁcial eﬀect of the
GLP-1 receptor agonists and even the DPP4 inhibitors on
β-cell function and mass are under way. Also, in type-2 diabetes,
an important role for inﬂammation in the progressive failure of
the β-cell function and even mass has been proposed. Thus, our
data may add to a better case for exploiting the incretin system
in both type-1 and type-2 diabetes as agents that may be
improving β-cell health.
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